LIGAND PHARMACEUTICALS INC

LGND

Form 4 • Statement of Changes in Beneficial Ownership

SEC Accession Number: 0001104659-26-023943
Filing date: Mar 5, 2026
Earliest execution date: Mar 3, 2026
Reporting Owners: Sabba Stephen L (Director)

Summary

Type

Sell

Net shares

-2,034

% of shares

-5.68%

Amount (USD)

$409,851

Insider confidence score

20.0 out of 100

Negative

  • Large discretionary sell (≥1% of shares)
  • Large sell amount ($250K+)

Stock transactions

Transaction 1

Security

Common Stock

Action

Exercise

Date

2026-03-03

Code

M

Net shares

+2,034.0

Price per Share

$69.51

Amount (USD)

$141,383.34

Acquired/Disposed

Acquired

Shares Owned Before

33,793.0

Shares Owned After

35,827.0

Transaction 2

Security

Common Stock

Action

Sell

Date

2026-03-03

Code

S

Net shares

-2,034.0

Price per Share

$201.50

Amount (USD)

$409,851.00

Acquired/Disposed

Disposed

Shares Owned Before

35,827.0

Shares Owned After

33,793.0

Derivative Transactions

Transaction 1

Security

Non- Qualified Stock Option (right to buy)

Action

Exercise

Date

2026-03-03

Code

M

Net shares

-2,034.0

Acquired/Disposed

Disposed

Shares Owned Before

2,034.0

Shares Owned After

0.0

Filing's footnotes

1. These securities, as represented in Column 5, includes the grant of 1,209 restricted shares approved by the Board of Directors of the Company at the Annual Meeting held June 6, 2025, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date (such meeting has not yet been held) or (b) on the first anniversary of the grant date, as reported on the Reporting Person's Form 4, dated 10 June 2025, which was filed to reflect the 2025 Meeting grant.

2. These securities, as represented in Column 5, were acquired by a grant of 2,329 shares approved by the Board of Directors of the Company at the 2016 Meeting, as previously reported on the Reporting Person's Form 4, dated 25 May 2016. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time. The original grant was adjusted to 2,034 shares and the exercise price adjusted to $69.51 pursuant to the OmniAb Inc. separation from the Company.

This page is for informational purposes only. While we strive for accuracy, the summary may contain inaccuracies or omissions. Please refer to the official SEC filing for authoritative information. Open the SEC filing.